Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Liquid biopsy biomarker could revolutionize bladder cancer diagnostics and treatment

Liquid biopsy biomarker could revolutionize bladder cancer diagnostics and treatment

Stories Jan 8, 2021 3 minutes

Researchers have developed a potential tumour DNA diagnostic test to better inform decision-making for bladder cancer treatment.

Liquid biopsies that examine circulating tumour DNA (ctDNA) could be a game changer in aggressive bladder cancer diagnostics, according to the findings of a new study led by Vancouver Coastal Health Research Institute (VCHRI) researcher Dr. Alexander Wyatt. The study was published in Nature Communications in January 2021. 

Wyatt’s discovery at the Vancouver Prostate Centre is the first step towards validating a tool to improve treatment outcomes for the most severely ill of the roughly 12,000 Canadians1 affected by bladder cancer each year.

“Our study results offer a paradigm shift in the way we diagnose bladder cancer.” 

ctDNA is cell-free DNA released from cancer cells in the body. Previous studies have shown that this potential biomarker acts as a barometer of cancer severity—the higher ctDNA concentrations found in a single blood draw, the greater the amount of cancer present in a patient’s body. 

In collaboration with VCHRI researcher and BC Cancer Agency medical oncologist Dr. Bernhard Eigl; PhD student Gillian Vandekerkhove; and co-authors, Wyatt examined the ctDNA of over 100 patients with metastatic bladder cancer, which occurs when the disease progresses and the cancer spreads to areas of the body beyond the bladder. This later-stage and more dangerous disease requires time-sensitive decisions about treatment courses.

Dr. Alexander Wyatt is a senior research scientist at the Vancouver Prostate Centre, a BC Cancer scientist and an assistant professor in the Department of Urologic Sciences at the University of British Columbia.

“For metastatic disease, chemotherapy used to be the only option,” says Wyatt. “There are now three or four alternative therapies for which patients are eligible, but clinicians cannot necessarily access the most up-to-date information on their patient’s disease to help decide what therapy to use.” 

ctDNA could be the new gold standard in diagnostics

The current gold standard approach to obtain information about a person’s cancer is a tissue sample surgically removed from the tumour. However, the invasive and costly nature of these extractions, which range from over $1,000 to upwards of $10-20,000 per procedure, means that they must be performed selectively in people with metastatic cancers. Also, for some patients with severe disease, additional surgeries may not be possible due to their weakened condition. 

A liquid biopsy, i.e., a blood draw, is non-invasive, costs less than $100, can be drawn anytime and returns up-to-date results within a matter of days, notes Wyatt.

“As we look to the future, we need to get information in real-time and have diagnostics that are representative of the present state of the disease. This is where the blood sample can really help us avoid subjecting patients to additional procedures or relying on tissue that was taken at an earlier time.” 

The ctDNA blood draw could help clinicians decide whether to stick with chemotherapy as a treatment course, apply immunotherapies or use therapies that target specific genomic mutations. 

“Circulating tumour DNA could add an extra layer of information about the genomic alterations in the tumour and disease severity, which will support an even more precise application of treatment.”

Liquid biopsies can also reveal treatment effectiveness in the event that ctDNA concentrations level off or decrease. 

“We still need to conduct additional studies to test whether ctDNA data is indeed clinically useful and can be applied to clinical practices,” says Wyatt. “Next, we aim to validate in clinical trials whether or not ctDNA profiling is a reliable tool that matches or exceeds the current gold standard of tissue profiling.”

 

1 Bladder Cancer Facts - Bladder Cancer Canada

Researchers

Alexander Wyatt

Related Articles

Cancer driver discovery opens up treatment pathways for rare pediatric disease

Transforming cervical cancer care

Computer-aided detection and diagnosis of colorectal cancer

Share:

  • Facebook
  • Linkedin
  • X
  • Email

Related Research Centres/Programs

Vancouver Prostate Centre

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Stories

Cancer driver discovery opens up treatment pathways for rare pediatric disease

Sep 25, 2023 cancer, treatment options, children
Type
Stories

People in profile: Karina Thiessen

Sep 20, 2023 people feature
Type
Stories

Sniffing sleuths: Canine disease detectives

Sep 9, 2023 innovation, COVID
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • X
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy